Inhibition of PCSK9 at the mRNA or protein levels is an efficacious strategy to lower LDL by increasing the density of LDL receptors on the hepatocyte surface. Evolocumab reduces plasma ApoB and ...

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?